VCN-01 (zabilugene almadenorepvec)
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Key Facts
Indication
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Phase
Phase 3
Status
Phase 3-ready; Positive End-of-Phase 2 FDA meeting
Company
About Theriva Biologics
Theriva Biologics is advancing a differentiated oncolytic virus platform engineered for systemic intravenous delivery, a key limitation of earlier therapies. Its lead candidate, VCN-01, has demonstrated promising clinical activity in metastatic pancreatic ductal adenocarcinoma (PDAC) and is positioned for a pivotal Phase 3 trial following a positive End-of-Phase 2 FDA meeting. The company's strategy focuses on leveraging its stroma-degrading and Albumin Shield™ technologies to treat difficult-to-treat solid tumors, both as monotherapy and in combination with chemotherapy and immunotherapy.
View full company profileTherapeutic Areas
Other Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Drugs
| Drug | Company | Phase |
|---|---|---|
| OMO-103 + SOC | Peptomyc | Phase 1b |
| Avutometinib + Defactinib | Verastem Oncology | Phase 1/2 |